What monitoring is used to assess progress during drug-resistant TB therapy?

• A. Serial sputum cultures with culture conversion, along with radiographic assessment and clinical evaluation.
• B. Daily weight measurement only
• C. Blood pressure and heart rate monitoring
• D. HIV testing only

Answer: (A)

Monitoring progress in drug-resistant TB therapy relies on microbiologic response tracked through serial sputum cultures, specifically watching for culture conversion, and this is best interpreted alongside radiographic imaging and clinical evaluation. Serial sputum cultures show whether the bacilli are still being shed; achieving culture conversion (typically two consecutive negative cultures or a defined milestone) indicates that the regimen is effectively reducing the bacterial burden. Radiographic assessment provides a view of the lung's structural changes and can reveal evolving lesions or complications, though imaging changes can lag behind microbiologic response. Clinical evaluation—how the patient feels, weight changes, cough, energy, and overall function—complements the microbiology and imaging, helping detect symptoms that might signal relapse, adherence issues, or drug-related adverse effects. Relying only on daily weight, or on vital signs or isolated tests like HIV screening, misses the essential microbiologic measure of cure or failure, which is why serial sputum cultures with culture conversion, plus imaging and clinical status, is the most informative monitoring approach.